Company intelligence / Profile preview

Gensciences

Nantong, Jiangsu Province, Chinacenterwatch.com ↗

Ownership: Private
Employees: ~500
Development stage: Phase 3

Overview

The company has four innovative drugs under clinical development and registration review. FRSW107 is under registration review, FRSW117 is in Phase III clinical trials, SS109 has completed Phase II clinical trials, and SS327 has been approved for clinical trials in China.

Therapeutic areas: HematologyOncologyMetabolic Disorders
Modalities: Fusion proteinsRecombinant coagulation factorsPEGylated proteins
Industry: Biotech

Drug pipeline

2 assets

pegylated recombinant human coagulation factor VIII-Fc fusion protein

1 more asset in the full pipeline.

Request access →

Partnerships

Foresee Pharma (Taiwan)

Beyond the preview

Go deeper on Gensciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gensciences.

Explore the full profile